FindTrial
Sign In

The role of LL-37 in the pathogenesis of Kawasaki disease

The mechanism of LL-37 participation in uncontrolled inflammatory responses in the pathogenesis of Kawasaki disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060982
Enrollment
Unknown
Registered
2022-06-14
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

KD group:no
Normal:no
pneumonia:no

Sponsors

Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, PR China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: It meets the diagnostic criteria of Kawasaki disease and has no immune disease within one week of onset without relevant treatment

Exclusion criteria

Exclusion criteria: Fever more than 10 days, after kawasaki disease related treatment, immune disease

Design outcomes

Primary

MeasureTime frame
LL37;—

Secondary

MeasureTime frame
TOLL4;NLRP3;—

Countries

China

Contacts

Public ContactFeifei Si
sifeifei211@163.com13688360952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026